$CYDY The Phase 2 clinical trial is a randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of leronlimab in patients with mild to moderate documented COVID-19 illness and calls for 75 planned patients in up to 10 centers in the United States. Patients enrolled in the trial are expected to have a treatment window of approximately 6 weeks.
We already have requests from many different countries (including US Gov't) and organizations, so we will begin to finalize those orders. We will provide a sense of the scale of this opportunity during the next few weeks.